Curated News
By: NewsRamp Editorial Staff
June 22, 2026

Onco-Innovations Raises C$5M to Boost Cancer Pipeline

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Onco-Innovations raised C$5M at C$0.7392/unit with warrants at C$0.90, offering leverage for early investors.
  • The private placement consists of 6.76M units, each with one share and a three-year warrant, closing around July 10, 2026.
  • Proceeds will advance ONC010 cancer treatment and SynoGraph platform, aiming to improve outcomes for solid tumour patients.
  • Securities issued under Canada's Listed Issuer Financing Exemption have no hold period, enabling immediate trading.

Impact - Why it Matters

This news matters because Onco-Innovations' funding will accelerate the development of potential cancer treatments, particularly through its ONC010 program and SynoGraph platform. For investors, it signals confidence in the company's technology and progress toward clinical milestones. For patients and the broader healthcare community, advancements in solid tumour therapy could lead to new, more effective treatment options, addressing a critical need in oncology. The use of the Listed Issuer Financing Exemption also streamlines the process, allowing faster access to capital without traditional hold periods.

Summary

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced a non-brokered private placement to raise approximately C$5 million. The offering consists of 6,764,069 units priced at C$0.7392 per unit, with each unit comprising one common share and one warrant exercisable at C$0.90 per share for three years. The financing is expected to close on or about July 10, 2026, pending regulatory approvals, including from Cboe Canada. This capital infusion will enable Onco-Innovations to advance its ONC010 program through manufacturing and preclinical testing, support the development of its SynoGraph(TM) platform, and provide working capital for general corporate purposes. The offering is conducted under Canada's Listed Issuer Financing Exemption, meaning the securities issued will not be subject to a hold period under applicable Canadian securities laws.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumours. This funding round signals a significant step forward in its pipeline, particularly for the ONC010 program, which focuses on novel cancer therapies. The company's strategic focus on oncology and its proprietary platforms positions it as a key player in the biotech sector, aiming to address unmet medical needs in cancer care.

For investors and stakeholders, this development highlights Onco-Innovations' commitment to advancing its clinical programs and expanding its technological footprint. The announcement was disseminated via NetworkNewsWire (NNW), a specialized communications platform that distributes financial news for public companies. As part of the Dynamic Brand Portfolio @ IBN, NNW provides broad reach through its network of wire solutions, editorial syndication to over 5,000 outlets, and social media distribution. The full press release is available at https://www.nnw.fm/QatCe, and the latest updates on ONNVF can be found in the company's newsroom at https://nnw.fm/ONNVF.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Raises C$5M to Boost Cancer Pipeline

blockchain registration record for this content.